AR029311A1 - UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS. - Google Patents
UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS.Info
- Publication number
- AR029311A1 AR029311A1 ARP990104280A ARP990104280A AR029311A1 AR 029311 A1 AR029311 A1 AR 029311A1 AR P990104280 A ARP990104280 A AR P990104280A AR P990104280 A ARP990104280 A AR P990104280A AR 029311 A1 AR029311 A1 AR 029311A1
- Authority
- AR
- Argentina
- Prior art keywords
- tolterodine
- related compounds
- unstable
- treatment
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Un método y formulacion para el tratamiento de la vejiga inestable o hiperactiva, en la cual se administra a un paciente una cantidad farmacéuticamente efectiva de tolterodina o un compuesto relacionado de tolterodina, o una sal farmacéuticamente aceptable de la misma, por medio de una formulacion de liberacion, controlada capaz de mantener un nivel sérico de actividad o actividades medias sustancialmente constante durante por lo menos 24 hs. Una formulacion farmacéutica que contiene tolterodina o un compuesto relacionado de tolterodina, o una sal de la misma farmacéuticamente aceptable, de liberacion controlada de tolterodina o un compuesto tolterodina relacionado, o una sal de la misma cuando se administra a pacientes. Preferentemente, la formulacion de liberacion controlada provee una media de índice de fluctuacion de dicho nivel sérico de actividad o actividades medias que no es mayor de aproximadamente 2,0 preferentemente no mayor de alrededor de 1,0 siendo definido dicho índice de fluctuacion, FI, como FI=(Cmax-Cmin)/AUCt/t, donde Cmax y Cmin son las concentraciones máxima y mínima, respectivamente, de la actividad o actividades medias, AUCt es el área bajo el perfil de la concentracion sérica y t es la longitud del intervalo de dosificacion. El uso de tolterodina o de un compuesto relacionado de tolterodina o una sal farmacéuticamente aceptable de la misma para la fabricacion de una formulacion terapéutica de liberacion controlada para el tratamiento de la vejiga inestable o hiperactiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802864A SE9802864D0 (sv) | 1998-08-27 | 1998-08-27 | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| SE9803871A SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Therapeutic method and formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029311A1 true AR029311A1 (es) | 2003-06-25 |
Family
ID=26663376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104280A AR029311A1 (es) | 1998-08-27 | 1999-08-26 | UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6770295B1 (es) |
| EP (2) | EP2153825A1 (es) |
| CN (1) | CN1239152C (es) |
| AP (1) | AP1529A (es) |
| AR (1) | AR029311A1 (es) |
| AT (1) | ATE487471T1 (es) |
| AU (1) | AU745190B2 (es) |
| BG (1) | BG65168B1 (es) |
| CA (1) | CA2311755C (es) |
| CY (1) | CY1111088T1 (es) |
| CZ (1) | CZ302630B6 (es) |
| DE (1) | DE69942928D1 (es) |
| DK (1) | DK1039882T3 (es) |
| EA (1) | EA002720B1 (es) |
| GE (1) | GEP20043354B (es) |
| HU (1) | HUP0100437A3 (es) |
| ID (1) | ID25824A (es) |
| IL (1) | IL136294A (es) |
| IS (1) | IS2976B (es) |
| ME (1) | ME00850B (es) |
| MY (1) | MY127946A (es) |
| NO (1) | NO329830B1 (es) |
| NZ (1) | NZ504618A (es) |
| OA (1) | OA11636A (es) |
| PT (1) | PT1039882E (es) |
| SI (1) | SI1039882T1 (es) |
| SK (1) | SK287111B6 (es) |
| TR (1) | TR200001998T1 (es) |
| UA (1) | UA72882C2 (es) |
| WO (1) | WO2000012069A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| DE19932651A1 (de) * | 1999-07-13 | 2001-01-18 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Tolterodin |
| KR100838930B1 (ko) | 1999-11-11 | 2008-06-16 | 화이자 헬스 에이비 | 톨테로딘을 포함하는 약학 제제 및 이의 용도 |
| DE10149674A1 (de) | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| JP2005512995A (ja) * | 2001-11-09 | 2005-05-12 | ファイザー ヘルス アーベー | 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト |
| US6773421B2 (en) | 2001-12-14 | 2004-08-10 | Kimberly-Clark Worlwide, Inc. | Combination for managing the involuntary loss of bladder control |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| PT1572173E (pt) * | 2002-12-13 | 2010-05-10 | Warner Lambert Co | Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior |
| WO2004064821A1 (en) † | 2003-01-22 | 2004-08-05 | Pfizer Health Ab | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| EP1635795A1 (en) * | 2003-05-30 | 2006-03-22 | Ranbaxy Laboratories, Ltd. | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
| AU2004289222B2 (en) | 2003-11-04 | 2010-01-21 | Supernus Pharmaceuticals Inc. | Compositions of quaternary ammonium containing bioavailability enhancers |
| JP5610663B2 (ja) | 2003-11-04 | 2014-10-22 | スパーナス ファーマシューティカルズ インコーポレイテッド | トロスピウムの１日１回剤形 |
| WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
| EP1629834A1 (en) * | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| RU2301086C2 (ru) * | 2004-12-27 | 2007-06-20 | Государственное образовательное учреждение высшего профессионального образования Алтайский государственный медицинский университет Минздрава России (ГОУ ВПО АГМУ МЗ РФ) | Способ лечения гиперактивного мочевого пузыря |
| CN1330297C (zh) * | 2005-07-04 | 2007-08-08 | 宛六一 | 酒石酸托特罗定软胶囊及其制备方法 |
| KR20070012205A (ko) * | 2005-07-22 | 2007-01-25 | 주식회사종근당 | 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛 |
| HUE056937T2 (hu) | 2006-02-03 | 2022-04-28 | Opko Renal Llc | A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal |
| EP2015735A1 (en) * | 2006-04-21 | 2009-01-21 | Synthon B.V. | Tolterodine beads |
| LT2679228T (lt) | 2006-06-21 | 2018-05-10 | Opko Ireland Global Holdings, Ltd. | Terapija naudojant vitamino d atstatymo agentą ir vitamino d hormoninį pakaitinį agentą |
| EP2148683A4 (en) | 2007-04-25 | 2012-09-12 | Proventiv Therapeutics Llc | SAFE AND EFFECTIVE METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDIA IN CHRONIC RENAL DISEASES |
| ES2401205T3 (es) | 2007-04-25 | 2013-04-17 | Cytochroma Inc. | Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo |
| CA2683628C (en) | 2007-04-25 | 2018-03-06 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| WO2009003724A1 (en) * | 2007-07-03 | 2009-01-08 | Synthon B.V. | Tolterodine bead |
| US8486452B2 (en) | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
| US20090192228A1 (en) * | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090214665A1 (en) * | 2008-02-26 | 2009-08-27 | Lai Felix S | Controlled Release Muscarinic Receptor Antagonist Formulation |
| US8962239B2 (en) | 2008-04-02 | 2015-02-24 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| TWI541246B (zh) | 2008-12-08 | 2016-07-11 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| KR101004205B1 (ko) * | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
| RU2396920C1 (ru) * | 2008-12-29 | 2010-08-20 | Николай Владимирович Карюкин | Способ лечения гиперактивного мочевого пузыря |
| WO2011095388A1 (en) | 2010-02-04 | 2011-08-11 | Synthon Bv | Tolterodine bead |
| KR101746204B1 (ko) * | 2010-02-18 | 2017-06-13 | 에스케이케미칼주식회사 | 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물 |
| EP3636280B1 (en) | 2010-03-29 | 2025-05-14 | EirGen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| EP2563123B1 (en) | 2010-04-30 | 2018-04-25 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| EP2601944B1 (en) * | 2010-08-03 | 2021-02-17 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal patch and method for augmenting adhesive strength thereof |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| SG10201913863TA (en) | 2016-03-28 | 2020-03-30 | Opko Ireland Global Holdings Limited | Methods of vitamin d treatment |
| EP3808336A1 (de) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| ATE185694T1 (de) | 1992-05-13 | 1999-11-15 | Alza Corp | Oxybutynin zur transdermalen verabreichung |
| SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| WO1996012477A1 (en) | 1994-10-21 | 1996-05-02 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| JP2000515525A (ja) | 1996-07-19 | 2000-11-21 | アベーグ，グンナー | 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン |
| JP2001502302A (ja) * | 1996-09-19 | 2001-02-20 | アメリカン・ホーム・プロダクツ・コーポレイション | 尿失禁を治療する方法 |
-
1999
- 1999-08-26 SI SI9931050T patent/SI1039882T1/sl unknown
- 1999-08-26 TR TR2000/01998T patent/TR200001998T1/xx unknown
- 1999-08-26 CA CA2311755A patent/CA2311755C/en not_active Expired - Lifetime
- 1999-08-26 AP APAP/P/2000/001823A patent/AP1529A/en active
- 1999-08-26 EP EP09173927A patent/EP2153825A1/en not_active Withdrawn
- 1999-08-26 OA OA1200000309A patent/OA11636A/en unknown
- 1999-08-26 CZ CZ20001924A patent/CZ302630B6/cs not_active IP Right Cessation
- 1999-08-26 NZ NZ504618A patent/NZ504618A/xx not_active IP Right Cessation
- 1999-08-26 PT PT99946521T patent/PT1039882E/pt unknown
- 1999-08-26 AT AT99946521T patent/ATE487471T1/de active
- 1999-08-26 UA UA2000052950A patent/UA72882C2/uk unknown
- 1999-08-26 AU AU58918/99A patent/AU745190B2/en not_active Expired
- 1999-08-26 DK DK99946521.4T patent/DK1039882T3/da active
- 1999-08-26 AR ARP990104280A patent/AR029311A1/es not_active Application Discontinuation
- 1999-08-26 SK SK749-2000A patent/SK287111B6/sk not_active IP Right Cessation
- 1999-08-26 US US09/582,498 patent/US6770295B1/en not_active Expired - Lifetime
- 1999-08-26 WO PCT/SE1999/001463 patent/WO2000012069A1/en not_active Ceased
- 1999-08-26 EA EA200000468A patent/EA002720B1/ru not_active IP Right Cessation
- 1999-08-26 ME MEP-2001-331A patent/ME00850B/me unknown
- 1999-08-26 MY MYPI99003665A patent/MY127946A/en unknown
- 1999-08-26 DE DE69942928T patent/DE69942928D1/de not_active Expired - Lifetime
- 1999-08-26 ID IDP20001006A patent/ID25824A/id unknown
- 1999-08-26 GE GE3951A patent/GEP20043354B/en unknown
- 1999-08-26 IL IL13629499A patent/IL136294A/en unknown
- 1999-08-26 EP EP99946521A patent/EP1039882B1/en not_active Revoked
- 1999-08-26 HU HU0100437A patent/HUP0100437A3/hu unknown
- 1999-08-26 CN CNB99801916XA patent/CN1239152C/zh not_active Expired - Lifetime
-
2000
- 2000-05-26 BG BG104476A patent/BG65168B1/bg unknown
- 2000-06-09 NO NO20002977A patent/NO329830B1/no not_active IP Right Cessation
- 2000-06-15 IS IS5537A patent/IS2976B/is unknown
-
2010
- 2010-11-17 CY CY20101101027T patent/CY1111088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029311A1 (es) | UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS. | |
| DK0804191T3 (da) | Anvendelse af inhibitorer for den fra blodplader hidhørende vækstfaktor-receptor til fremstilling af et lægmiddel til behan | |
| AR035863A1 (es) | Ligandos receptores de melanocortina | |
| MX9204881A (es) | Composicion farmaceutica que comprende moleculas activas, receptoras de calcio. | |
| RU2002132882A (ru) | Кожные композиции, содержащие кофермент q в качестве активного ингредиента | |
| DE69725860T2 (de) | PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
| CH667993A5 (de) | Pharmazeutische formulierungen zur behandlung von gedaechtnisstoerungen. | |
| DE3575927D1 (de) | Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung. | |
| RU2005135958A (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5, 8, 14-триазатетрацикло[10.3.1.02,11.04,9]-гексадека-2( 11 ), 3,5,7,9-пентаена | |
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| DE3778770D1 (de) | Neue diphenylpropylamin-derivate, ihre herstellung sowie ihre pharmazeutische verwendung. | |
| Bergman et al. | Some behavioral effects of histamine H1 antagonists in squirrel monkeys. | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| NO980793D0 (no) | Anvendelse av aminoadamantanforbindelse som immunregulatorer | |
| KR950031085A (ko) | 표피증식 질환 치료용 의약 조성물 | |
| ES2058148T3 (es) | N-benzopiranil-lactamas sustituidas con alquilo, procedimiento para su preparacion, su empleo, asi como preparados farmaceuticos a base de estos compuestos. | |
| DK0488928T3 (da) | Pharmaceutiske formuleringer, der indeholder en blanding af højere, primære, alifatiske alkoholer, til behandling af hyperc | |
| RU2003113987A (ru) | Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны | |
| CA2165446C (en) | Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade | |
| ES2036560T3 (es) | Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. | |
| CA2454544A1 (en) | Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| US20110196035A1 (en) | Temporally-Controlled Treatment of Joint Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |